GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: alpha-Tocotrienol quinone [3] | ATQ3 | EPI-743 | EPI743 | PTC-743 | PTC743
Compound class:
Synthetic organic
Comment: Vatiquinone (EPI-743; PTC-743) is an arachidonate 15-lipoxygenase (ALOX15) inhibitor [1]. It is orally bioavailable and crosses the blood-brain barrier.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Vatiquinone (EPI-743) was developed as a potential therapeutic for inherited respiratory chain mitochondrial diseases [1-2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01721733 | Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome | Phase 2 Interventional | PTC Therapeutics | ||
| NCT01822249 | Phase 2 Study of EPI-743 for Treatment of Rett Syndrome | Phase 2 Interventional | Edison Pharmaceuticals Inc | ||
| NCT05515536 | A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia | Phase 3 Interventional | PTC Therapeutics | ||
| NCT05218655 | A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease | Phase 3 Interventional | PTC Therapeutics | ||